Opportunity Information: Apply for PA 12 258
Apply for PA 12 258
- The National Institutes of Health in the food and nutrition health sector is offering a public funding opportunity titled "New Technologies for the Study of Lymphatics in the Digestive and Urinary Systems (R43/R44)" and is now available to receive applicants.
- Interested and eligible applicants and submit their applications by referencing the CFDA number(s): 93.847 Diabetes, Digestive, and Kidney Diseases Extramural Research.
- This funding opportunity was created on Aug 8, 2012 and posted on Aug 8, 2012.
- Applicants must submit their applications by Sep 7, 2015. (Agency may still review applications by suitable applicants for the remaining/unused allocated funding in 2026.)
- Each selected applicant is eligible to receive up to $150,000.00 in funding.
- Eligible applicants include: Small businesses.
[Watch] Creating a grant proposal using the step-by-step wizard inside the applicant portal:
Opportunity Summary:
New Technologies for the Study of Lymphatics in the Digestive and Urinary Systems (R43/R44) is a National Institutes of Health (NIH) Small Business Innovation Research (SBIR) funding opportunity that seeks to stimulate the creation and early development of practical research reagents, tools, and enabling technologies that will speed up scientific progress on lymphatic vessels specifically within digestive system organs and the urinary tract. The central idea is to support small businesses that can build or refine technologies that help researchers better measure, visualize, model, or otherwise interrogate lymphatic vessel physiology (how lymphatic vessels function in normal conditions) and pathophysiology (how that function changes in inflammation or disease) in these organ systems. While lymphatics are often studied in the context of immunology, this announcement explicitly states that immune mechanisms are not the main focus; instead, it prioritizes tools that make it easier to understand the local functional anatomy and physiology of lymphatic vessels and how disruptions to lymphatic function can influence organ performance in the gut and urinary tract.
This opportunity is issued as a Program Announcement (PA 12-258) under the NIH SBIR mechanism using the R43 and R44 grant activity codes, which correspond to the typical SBIR Phase I and Phase II pathway. In practical terms, that means it is designed for small businesses that want to move a technology from concept and feasibility testing (Phase I) toward further development and validation (Phase II), with the broader goal of producing something the research community can actually use. The FOA is categorized as a discretionary grant program and is associated with NIH’s mission area covering diabetes, digestive, and kidney diseases (CFDA 93.847), reflecting the relevance of lymphatic biology to gastrointestinal and urinary tract health and disease.
The scientific scope centers on technologies that can clarify what determines lymphatic vessel structure and function at the local tissue level across different physiological states, including health, inflammation, and disease. It also emphasizes interest in technologies that help unpack how changes in lymphatic vessel function can alter organ function, which could include effects on fluid balance, lipid transport, tissue edema, mucosal barrier integrity, nutrient absorption, motility, or local tissue remodeling depending on the organ context. Even though the announcement is not aimed at immune biology per se, it leaves room for tools that indirectly support such studies as long as the primary value is advancing understanding of lymphatic vessel functional anatomy and physiology in digestive and urinary tract tissues. In other words, a tool does not become out of scope just because it can be used in immunology; it becomes out of scope if it is designed mainly to probe immune mechanisms rather than lymphatic vessel function and its organ-level consequences.
From an applicant and administrative standpoint, eligibility is limited to small businesses, consistent with SBIR requirements, and there is no cost sharing or matching requirement. The archived solicitation information indicates an award ceiling listed at $150,000 (often aligning with Phase I scale in many SBIR contexts), and the opportunity was originally posted on August 8, 2012, with a closing date of September 7, 2015, and an archive date of October 8, 2015, meaning it is no longer open for new applications under that specific posting. The funding opportunity number is PA 12-258, and the full announcement was hosted through the NIH grants guide page (at the link provided in the source data). For access issues or linking problems, the listed contact was the NIH Office of Extramural Research (OER) webmaster at FBOWebmaster@OD.NIH.GOV.
Overall, the FOA can be read as an NIH push to strengthen the technology base for lymphatics research where the digestive and urinary systems are concerned, by leveraging small business innovation to create broadly usable research enablers. The intended outputs are not general research findings alone, but tangible tools, reagents, and technology platforms that remove technical bottlenecks and allow many labs to study how lymphatic vessels are organized, how they function in living tissues, what changes during disease, and how those lymphatic changes feed back into organ dysfunction.
Frequently Asked Questions (FAQs)
What is the name of this funding opportunity?
The opportunity is titled New Technologies for the Study of Lymphatics in the Digestive and Urinary Systems (R43/R44).
Which agency is offering this opportunity?
This is a National Institutes of Health (NIH) funding opportunity.
What funding mechanism does this use?
It is offered under the NIH Small Business Innovation Research (SBIR) program using R43/R44 activity codes, which correspond to the typical SBIR Phase I (R43) and SBIR Phase II (R44) pathway.
What is the FOA number?
The funding opportunity number is PA 12-258.
Is this a Program Announcement (PA)?
Yes. It is issued as a Program Announcement (PA) under PA 12-258.
What is the main purpose of this SBIR opportunity?
The goal is to stimulate the creation and early development of practical research reagents, tools, and enabling technologies that speed up scientific progress on lymphatic vessels specifically within digestive system organs and the urinary tract.
What kinds of outputs is NIH looking for?
The emphasis is on tangible, broadly usable research enablers such as tools, reagents, and technology platforms that remove technical bottlenecks and allow many labs to study lymphatic vessels in digestive and urinary tissues. The intent is not limited to publishing findings; it is aimed at producing technologies the research community can actually use.
What scientific area does this opportunity focus on?
The scientific scope centers on technologies that improve the ability to measure, visualize, model, or otherwise interrogate lymphatic vessel physiology and pathophysiology in the digestive system and urinary tract, including in health, inflammation, and disease.
What does the FOA mean by lymphatic vessel physiology and pathophysiology?
In this FOA, physiology refers to how lymphatic vessels function under normal conditions, and pathophysiology refers to how that function changes during inflammation or disease within digestive organs and the urinary tract.
What organ systems are specifically included?
The FOA targets lymphatic vessels within digestive system organs and the urinary tract.
Does the FOA prioritize immune mechanisms or immunology-focused projects?
No. While lymphatics are often studied in immunology, this announcement explicitly states that immune mechanisms are not the main focus. It prioritizes tools that improve understanding of the local functional anatomy and physiology of lymphatic vessels and how disruptions to lymphatic function influence organ performance in the gut and urinary tract.
Are tools that can also be used for immunology automatically out of scope?
Not necessarily. The FOA notes that a tool does not become out of scope simply because it could be used in immunology. It becomes out of scope if it is designed mainly to probe immune mechanisms rather than to advance understanding of lymphatic vessel function and its organ-level consequences in digestive and urinary tissues.
What types of biological or functional questions does the FOA want technologies to help answer?
The FOA emphasizes technologies that clarify what determines lymphatic vessel structure and function at the local tissue level across different physiological states. It also highlights interest in technologies that help unpack how changes in lymphatic vessel function can alter organ function in the gut and urinary tract.
What are examples of organ-level consequences mentioned in the FOA?
The FOA mentions potential effects that could be studied with relevant technologies, including impacts on fluid balance, lipid transport, tissue edema, mucosal barrier integrity, nutrient absorption, motility, and local tissue remodeling, depending on the organ context.
Who is eligible to apply?
Eligibility is limited to small businesses, consistent with SBIR requirements.
Is cost sharing or matching required?
No. The FOA states there is no cost sharing or matching requirement.
What is the award ceiling listed for this opportunity?
The archived solicitation information indicates an award ceiling listed at $150,000 (noted as often aligning with Phase I scale in many SBIR contexts).
What is the program category of this grant?
The FOA is categorized as a discretionary grant program.
What NIH mission area or CFDA number is associated with this opportunity?
It is associated with NIH’s mission area covering diabetes, digestive, and kidney diseases, with CFDA 93.847.
When was this opportunity originally posted?
The opportunity was originally posted on August 8, 2012.
What was the closing date for applications under this posting?
The closing date listed was September 7, 2015.
Is this funding opportunity still open?
No. The information provided indicates it is archived and no longer open for new applications under that specific posting.
When was the opportunity archived?
The archive date listed is October 8, 2015.
Where was the full announcement hosted?
The full announcement was hosted through the NIH grants guide page (at the link provided in the source data referenced by the opportunity description).
Who was listed as a contact for access issues or linking problems?
The listed contact for access or linking issues was the NIH Office of Extramural Research (OER) webmaster at FBOWebmaster@OD.NIH.GOV.
What is the overall intent of NIH with this FOA?
The FOA represents an NIH push to strengthen the technology base for lymphatics research in the digestive and urinary systems by leveraging small business innovation to create research enablers that help many labs study how lymphatic vessels are organized, how they function in living tissues, what changes during disease, and how those changes contribute to organ dysfunction.
How do Phase I and Phase II fit into this opportunity?
The R43/R44 structure is intended to support moving a technology from concept and feasibility testing (Phase I) toward further development and validation (Phase II), with the broader goal of producing something usable by the research community.
Browse more opportunities from the same category: Food and Nutrition Health
Next opportunity: Lymphatics in Health and Disease in the Digestive, Urinary, Cardiovascular and Pulmonary Systems (R01)
Previous opportunity: Office of Special Education and Rehabilitative Services (OSERS) Assistive Technology Alternative Financing Program CFDA Number 84.224D
USGrants.org Applicant Portal:
Are you interested in learning about about how to apply for this government funding opportunity? You can create a free applicant account and receive instant access to our applicant portal that many business owners like you have benefited from.
Apply for PA 12 258
[Watch] how do funding administrators access proposals?
Applicants also applied for:
Applicants who have applied for this opportunity (PA 12 258) also looked into and applied for these:
| Funding Opportunity |
|---|
| Lymphatics in Health and Disease in the Digestive, Urinary, Cardiovascular and Pulmonary Systems (R01) Apply for PAR 12 259 Funding Number: PAR 12 259 Agency: National Institutes of Health Category: Food and Nutrition Health Funding Amount: $250,000 |
| Lymphatics in Health and Disease in the Digestive, Cardiovascular and Pulmonary Systems (R21) Apply for PAR 12 260 Funding Number: PAR 12 260 Agency: National Institutes of Health Category: Food and Nutrition Health Funding Amount: $125,000 |
| Ancillary Studies to Major Ongoing Clinical Research Studies to Advance Areas of Scientific Interest within the Mission of the NIDDK (R01) Apply for PAR 12 265 Funding Number: PAR 12 265 Agency: National Institutes of Health Category: Food and Nutrition Health Funding Amount: Case Dependent |
| Limited Competition for the Continuation of the Assessment, Serial Evaluation and Subsequent Sequelae of Acute Kidney Injury (ASSESS AKI) Study (U01) Apply for RFA DK 12 509 Funding Number: RFA DK 12 509 Agency: National Institutes of Health Category: Food and Nutrition Health Funding Amount: Case Dependent |
| Pilot Studies of Candidate Therapies for Chronic Kidney Disease (CKD) (U01) Apply for RFA DK 12 016 Funding Number: RFA DK 12 016 Agency: National Institutes of Health Category: Food and Nutrition Health Funding Amount: Case Dependent |
| Expansion of Symptoms of Lower Urinary Tract Dysfunction Research Network (LURN) (U01) Apply for RFA DK 12 017 Funding Number: RFA DK 12 017 Agency: National Institutes of Health Category: Food and Nutrition Health Funding Amount: Case Dependent |
| Limited Competition for the Continuation of the Chronic Renal Insufficiency Cohort (CRIC) Study (U01) Apply for RFA DK 12 508 Funding Number: RFA DK 12 508 Agency: National Institutes of Health Category: Food and Nutrition Health Funding Amount: Case Dependent |
| Advancing Clinical Research in Primary Glomerular Diseases (UM1) Apply for RFA DK 12 014 Funding Number: RFA DK 12 014 Agency: National Institutes of Health Category: Food and Nutrition Health Funding Amount: Case Dependent |
| Novel Interventions to Reduce Morbidity and Mortality of Hemodialysis Patients Safety and Other Early Phase Studies (U01) Apply for RFA DK 12 010 Funding Number: RFA DK 12 010 Agency: National Institutes of Health Category: Food and Nutrition Health Funding Amount: Case Dependent |
| Multidisciplinary K12 Urologic Research (KURe) Career Development Program Apply for RFA DK 12 013 Funding Number: RFA DK 12 013 Agency: National Institutes of Health Category: Food and Nutrition Health Funding Amount: $600,000 |
| Limited Competition Small Grant Program for NIDDK K01/K08/K23 Recipients (R03) Apply for PAR 12 285 Funding Number: PAR 12 285 Agency: National Institutes of Health Category: Food and Nutrition Health Funding Amount: $50,000 |
| George M. OBrien Urology Cooperative Research Centers Program (U54) Apply for RFA DK 12 009 Funding Number: RFA DK 12 009 Agency: National Institutes of Health Category: Food and Nutrition Health Funding Amount: $650,000 |
| Ancillary Studies of Acute Kidney Injury, Chronic Kidney Disease, and End Stage Renal Disease Accessing Information from Clinical Trials, Epidemiological Studies, and Databases (R01) Apply for PA 12 299 Funding Number: PA 12 299 Agency: National Institutes of Health Category: Food and Nutrition Health Funding Amount: Case Dependent |
| Early Stage Pharmacological Validation of Novel Targets and Accompanying Pre Therapeutic Leads for Diseases of Interest to the NIDDK (R01) Apply for PAR 13 007 Funding Number: PAR 13 007 Agency: National Institutes of Health Category: Food and Nutrition Health Funding Amount: $500,000 |
| New Directions in Hematology Research (SHINE II) (R01) Apply for PAS 13 006 Funding Number: PAS 13 006 Agency: National Institutes of Health Category: Food and Nutrition Health Funding Amount: $200,000 |
| Limited Competition Data Coordinating Center for The Environmental Determinants of Diabetes in the Young (TEDDY) Study (UC4) Apply for RFA DK 12 510 Funding Number: RFA DK 12 510 Agency: National Institutes of Health Category: Food and Nutrition Health Funding Amount: Case Dependent |
| Research Using Biosamples from Selected Type 1 Diabetes Clinical Studies (DP3) Apply for PAR 13 013 Funding Number: PAR 13 013 Agency: National Institutes of Health Category: Food and Nutrition Health Funding Amount: Case Dependent |
| Developmental Centers for Interdisciplinary Research in Benign Urology (P20) Apply for RFA DK 12 022 Funding Number: RFA DK 12 022 Agency: National Institutes of Health Category: Food and Nutrition Health Funding Amount: $200,000 |
| Nociceptive GenitoUrinary Development Molecular Anatomy Projects (nGUDMAP) (U01) Apply for RFA DK 12 024 Funding Number: RFA DK 12 024 Agency: National Institutes of Health Category: Food and Nutrition Health Funding Amount: Case Dependent |
| Research Using Subjects From Selected Type 1 Diabetes Clinical Studies (Living Biobank) (DP3) Apply for PAR 13 028 Funding Number: PAR 13 028 Agency: National Institutes of Health Category: Food and Nutrition Health Funding Amount: Case Dependent |
Grant application guides and resources
It is always free to apply for government grants. However the process may be very complex depending on the funding opportunity you are applying for. Let us help you!
Apply for Grants
Premium leads for funding administrators, grant writers, and loan issuers
Thousands of people visit our website for their funding needs every day. When a user creates a grant proposal and files for submission, we pass the information on to funding administrators, grant writers, and government loan issuers.
If you manage government grant programs, provide grant writing services, or issue personal or government loans, we can help you reach your audience.
Subscribe to Leads
Request more information:
Would you like to learn more about this funding opportunity, similar opportunities to "PA 12 258", eligibility, application service, and/or application tips? Submit an inquiry below:
Don't forget to subscribe to our grant alerts mailing list to receive weekly alerts on new and updated grant funding opportunities like this one in your email.